Abstract
Background/Aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.
Materials and Methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease’s patients treated for different solid tumors.
Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.
Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
Keywords: Inflammatory bowel diseases, radiotherapy, toxicity.
Reviews on Recent Clinical Trials
Title:Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Volume: 9 Issue: 1
Author(s): Tolia Maria, Zygogianni Anna, Kouvaris John R., Tsoukalas Nikolaos, Kokakis Ioannis, Kyrgias George, Mystakidou Kyriaki and Kouloulias Vasileios
Affiliation:
Keywords: Inflammatory bowel diseases, radiotherapy, toxicity.
Abstract: Background/Aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.
Materials and Methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease’s patients treated for different solid tumors.
Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.
Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
Export Options
About this article
Cite this article as:
Maria Tolia, Anna Zygogianni, R. John Kouvaris, Nikolaos Tsoukalas, Ioannis Kokakis, George Kyrgias, Kyriaki Mystakidou and Vasileios Kouloulias, Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review, Reviews on Recent Clinical Trials 2014; 9 (1) . https://dx.doi.org/10.2174/1574887109666140423123845
DOI https://dx.doi.org/10.2174/1574887109666140423123845 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention
Current Drug Targets Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Current Molecular Medicine New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC)
Current Drug Targets Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect
Endocrine, Metabolic & Immune Disorders - Drug Targets Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma
Current Drug Safety Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Quantitative Determination and Validation of Four Phenolic Acids in <i>Salvia Miltiorrhiza</i> Bunge using <sup>1</sup>H-NMR Spectroscopy
Current Pharmaceutical Analysis Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Autoantibody Reaction to Myelin Basic Protein by Plasma Parvovirus B19 IgG in MS Patients
Protein & Peptide Letters Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Therapeutic Targets of Misguided T Cells in Systemic Lupus Erythematosus
Current Drug Targets - Inflammation & Allergy Hydroxysafflor Yellow A Attenuates Renal Ischemia- Reperfusion Injury in a Rat Model
Letters in Drug Design & Discovery How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design Pentraxin 3 Serum Levels in Celiac Patients: Evidences and Perspectives
Recent Patents on Food, Nutrition & Agriculture